Elli Francesca Marta, Linglart Agnès, Garin Intza, de Sanctis Luisa, Bordogna Paolo, Grybek Virginie, Pereda Arrate, Giachero Federica, Verrua Elisa, Hanna Patrick, Mantovani Giovanna, Perez de Nanclares Guiomar
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (F.M.E., E.V., P.B., G.M.), Department of Clinical Sciences and Community Health, University of Milan, Endocrinology and Diabetology Unit, Milan, Italy; APHP (A.L., V.G., P.H.), Reference Center for Rare Disorders of the Mineral Metabolism and Plateforme d'expertise Paris Sud Maladies Rares, Le Kremlin Bicêtre, France; INSERM U1169 (A.L., V.G., P.H.), Hôpital Bicêtre, Le Kremlin Bicêtre, et Université Paris-Saclay, France; Molecular (Epi)Genetics Laboratory (I.G., A.P., G.P.d.N.), BioAraba National Health Institute, Hospital Universitario Araba-Txagorritxu, Vitoria-Gasteiz, Spain; Department of Public Health and Pediatrics (L.d.S., F.G.), University of Turin, Regina Margherita Children's Hospital, Health and Science City, Turin, Italy; Department of Biochemistry and Molecular Biology (A.P.), University of Basque Country, Leioa, Spain.
J Clin Endocrinol Metab. 2016 Oct;101(10):3657-3668. doi: 10.1210/jc.2015-4310. Epub 2016 Jul 18.
The term pseudohypoparathyroidism (PHP) was coined to describe the clinical condition resulting from end-organ resistance to parathormone (rPTH), caused by genetic and/or epigenetic alterations within or upstream of GNAS. Although knowledge about PHP is growing, there are few data on the prevalence of underlying molecular defects.
The purpose of our study was to ascertain the relative prevalence of PHP-associated molecular defects.
With a specially designed questionnaire, we collected data from all patients (n = 407) clinically and molecularly characterized to date by expert referral centers in France, Italy, and Spain.
Isolated rPTH (126/407, 31%) was caused only by epigenetic defects, 70% of patients showing loss of imprinting affecting all four GNAS differentially methylated regions and 30% loss of methylation restricted to the GNAS A/B:TSS-DMR. Multihormone resistance with no Albright's hereditary osteodystrophy (AHO) signs (61/407, 15%) was essentially due to epigenetic defects, although 10% of patients had point mutations. In patients with rPTH and AHO (40/407, 10%), the rate of point mutations was higher (28%) and methylation defects lower (about 70%). In patients with multihormone resistance and AHO (155/407, 38%), all types of molecular defects appeared with different frequencies. Finally, isolated AHO (18/407, 4%) and progressive osseous heteroplasia (7/407, 2%) were exclusively caused by point mutations.
With European data, we have established the prevalence of various genetic and epigenetic lesions in PHP-affected patients. Using these findings, we will develop objective criteria to guide cost-effective strategies for genetic testing and explore the implications for management and prognosis.
假性甲状旁腺功能减退症(PHP)这一术语用于描述因GNAS内部或上游的基因和/或表观遗传改变导致终末器官对甲状旁腺激素(PTH)抵抗而产生的临床病症。尽管关于PHP的知识不断增加,但关于潜在分子缺陷患病率的数据却很少。
我们研究的目的是确定PHP相关分子缺陷的相对患病率。
通过一份专门设计的问卷,我们收集了法国、意大利和西班牙的专家转诊中心迄今在临床和分子水平上进行过特征分析的所有患者(n = 407)的数据。
孤立性PTH抵抗(126/407,31%)仅由表观遗传缺陷引起,70%的患者表现为印记缺失,影响所有四个GNAS差异甲基化区域,30%的患者甲基化缺失仅限于GNAS A/B:TSS-DMR。无艾布赖特遗传性骨营养不良(AHO)体征的多激素抵抗(61/407,15%)主要归因于表观遗传缺陷,尽管10%的患者存在点突变。在伴有PTH抵抗和AHO的患者(40/407,10%)中,点突变率更高(28%),甲基化缺陷更低(约70%)。在伴有多激素抵抗和AHO的患者(155/407,38%)中,所有类型的分子缺陷出现频率各不相同。最后,孤立性AHO(18/407,4%)和进行性骨化性纤维发育异常(7/407,2%)完全由点突变引起。
基于欧洲的数据,我们确定了PHP患者中各种基因和表观遗传病变的患病率。利用这些发现,我们将制定客观标准,以指导具有成本效益的基因检测策略,并探索其对管理和预后的影响。